GLP-1 drugs and the rearticulation of fat stigma in Spain: public responses to pharmaceuticalization of fat

GLP-1 agonists (e.g. Ozempic, Wegovy, Mounjaro) have been framed as breakthrough drugs for weight loss, often promoted by pharmaceutical companies under the guise of tackling weight stigma. This study examines public discourse surrounding GLP-1 agonists in Spanish digital news media, focusing on how these drugs are discussed in relation to fatness, moralization, medicalization, and pharmaceuticalization. Drawing on a reflexive thematic analysis of 648 user comments posted between 2022 and 2024 in three Spanish media outlets, we identify key narrative patterns shaping public debate. Our findings reveal three interrelated themes. First, discussions of GLP-1s are deeply embedded in fatphobic moralization. Pharmacological weight loss is frequently portrayed as a form of “cheating,” contrasted with supposedly “legitimate” weight loss achieved through effort, reproducing hierarchies that distinguish between “deserving” and “undeserving” fat bodies. Second, these hierarchies extend into debates about public healthcare funding. While users articulated four stances from full public funding to outright refusal, all remained anchored in logics of blame and deservingness, framing fatness as an individual or social burden rather than as a legitimate form of embodiment. Third, although commenters expressed strong skepticism toward pharmaceutical companies and media outlets, often criticizing profit-making and medicalization, this critique did not align with fat-acceptance perspectives and ultimately reinforced the weight-centered health paradigm by leaving intact the assumption that body weight is the primary marker of health and the central object of intervention. Overall, public discourse on GLP-1 agonists in Spain reproduces and reorganizes anti-fat frameworks through processes of pharmaceuticalization.